 |
Woohyun Lee, Chairman of OCI Holdings. (Photo=OCI Holdings) |
[Alpha Biz=(Chicago) Reporter Kim Jisun] OCI Group has suspended the integration process with Hanmi Pharmaceutical Group.
OCI Holdings, the holding company of OCI Group, said in an official statement on the 28th, "We humbly accept the will of the shareholders. The integration process with Hanmi Pharmaceutical will be suspended."
Also, OCI Holdings dismissed the possibility of re-promotion. OCI Holdings said, "There is no plan to re-promote" and "we hope for the development of Hanmi Pharmaceutical Group in the future."
At the Korea-U.S. Science shareholders' meeting, Chairman Lee Woo-hyun's agenda as an in-house director failed to pass. Lim Joo-hyun, vice chairman of Hanmi Science, who led the merger, also failed to become an in-house director because he failed to meet the majority of the votes.
On the other hand, Lim Jong-yoon and Jong-hoon, former presidents of Hanmi Pharmaceutical Group, the first and second sons of the former chairman of Hanmi Pharmaceutical Group, who opposed the merger, became internal directors. In the end, the integration process announced in January could not be carried out.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
